Founded in 2020, eMedicals Healthtech operates at the intersection of biosciences and healthtech, developing a plant biochemical platform for novel therapeutics while also pioneering next generation AI analytics and biomarkers for Chronic Kidney Disease (CKD) and Cardiometabolic Diseases.
Through our advanced R&D results, eMedicals secured funding from research excellence programs supported by the German Federal Ministry of Research, Technology, and Space, the German Federal Ministry of Education and Research and the Hessian Ministry of Science and Art.
In 2022, we further strengthened our position by securing equity investment from investors and obtaining a substantial bank loan, underscoring the robust support for our innovative approach.
Providing value for multiple stakeholders
Pharma
We aim to provide an innovative plant-based API production and delivery system that utilizes plant matrices to deliver active pharmaceutical ingredients, improving medication efficacy and patient adherence.
Patients
Our in-house developed AI-tools enable patients to synergistically manage their medication, diet, and health data, helping to reduce pill and injectable use, shorten hospital stays, or delay the need for dialysis.
Clinicians
Our Clinical Decision Support System (CDSS) streamlines doctors' daily workflows and enhances the quality of therapy decisions through advanced medical visual analytics tools.
Insurers
Our products have the potential to generate significant cost savings by reducing medication and hospitalisation
